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Abstract 
 
Background: Bronchoscopic therapies to reduce lung volumes in COPD are intended 
to avoid the risks associated with lung volume reduction surgery, or to be used in 
patient groups in whom LVRS is not appropriate. Aims: Bronchoscopic lung volume 
reduction, using endobronchial valves, to target unilateral lobar occlusion can 
improve lung function and exercise capacity in patients with emphysema. Benefit is 
most pronounced in, though not confined to, patients where lobar atelectasis occurred. 
Few data exist on their long term outcome.  Methods: 19 patients (16 male) FEV1 
28.4(11.9) underwent BLVR between July 2002 and February 2004. Radiological 
atelectasis was observed in 5 patients. Survival data to February 2010 was available 
for all patients. Results: None of the patients in whom atelectasis occurred died 
during follow up whereas 8 out of 14 in the non-atelectasis group died (Chi2 p=0.026). 
There was no significant difference between the groups at baseline in lung function, 
quality of life, exacerbation rate, exercise capacity (shuttle walk test or cycle 
ergometry) or CT appearances, although BMI was significantly higher in the 
atelectasis group 21.6(2.9) vs 28.4(2.9)kg.m-2 (p<0.001). Conclusions These data 
suggest that atelectasis following BLVR is associated with a survival benefit which is 
not explained by baseline differences. 
 
Keywords Emphysema, mortality, interventional bronchoscopy 
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INTRODUCTION 
 
Despite optimal pharmacological therapy and pulmonary rehabilitation, patients with 
chronic obstructive pulmonary disease remain significantly disabled. Lung volume 
reduction surgery (LVRS) has been clearly shown to improve outcomes in selected 
patient groups [1-3]. The surgical intervention is however, associated with significant 
morbidity and an early mortality rate of about 5% [1, 2]. There is considerable interest 
in developing novel treatment approaches that can reduce lung volumes and gas 
trapping, either more safely than LVRS, or else in patients for whom LVRS is not an 
option [4]. These include: the placement of endobronchial valves to prevent airflow to 
worst affected areas; the PneumRxTM coil to compress emphysematous lung; the 
creation of airway bypasses to allow trapped gas to escape and the bronchoscopic 
instillation of biologic agents to achieve volume reduction [4-17]. 
 
As this is a rapidly developing area, few data exist regarding the long term outcome of 
these approaches. There is an urgent need for therapies that might improve prognosis 
in COPD. Although pharmacological therapies are effective in relieving 
breathlessness and improving exercise capacity and quality of life, only smoking 
cessation and, in the most hypoxic individuals, oxygen therapy, have been shown to 
improve survival. In 2005 the authors published a case series describing the effect of 
bronchoscopic lung volume reduction (BLVR), using the EmphasysTM valves in 
patients with severe emphysema. The procedure was associated with improvements in 
exercise capacity that were most pronounced in, but not confined to, individuals with 
radiological atelectasis[14].  It is not known whether success of the procedure is 
associated with long term benefit.  This knowledge would inform the ongoing debate 
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as to whether lobar atelectasis should be the target of valve therapy. This approach 
involves all segments of a target lobe being occluded and patients selected according 
to the presence of intact interlobar fissures, a marker of the absence of interlobar 
collateral ventilation. However the occurrence of atelectasis may increase the risk of 
pneumothorax as the lung tissue remodels[9] and since some benefit occurs in the 
absence of atelectasis some investigators prefer a less extensive strategy without lobar 
occlusion[16].  Long term survival of patients from the authors’ original study was 




Between July 2002 and February 2004 19 patients (16 male), FEV1 28.4(11.9) 
%predicted underwent BLVR at The Royal Brompton Hospital.  Vital status was 
established for all the participants up to February 2010 (i.e. 6 years after the last 
procedure was completed) and survival data censored at 6 years. Clinical records were 
also reviewed for evidence of late complications that might have been due to the 
valves such as pneumothorax or distal pneumonia.  Where patients had died a copy of 
their death certificate was obtained to establish the cause of death. 
 
A full description of the original trial cohort, methods and four week outcomes has 
been published previously [14]. To recap briefly, patients were eligible to participate 
if they had COPD consistent with the GOLD guidelines [18], significant dyspnoea 
despite optimum medical therapy including pulmonary rehabilitation and a 
heterogeneous pattern of disease with a target area identified by CT scanning and 
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ventilation perfusion scintigraphy [15]. The Royal Brompton Hospital’s Research 
Ethics Committee approved the study and patients gave their informed consent. 
 
Endobronchial occlusion was performed using one-way valves (Emphasys Medical, 
Inc, Redwood City, Ca), placed to occlude segmental bronchi leading to the most 
affected area of lung. All procedures were unilateral. Initially, valves were inserted on 
a single occasion under general anaesthesia [15, 19]. Subsequently some procedures 
were carried out with sedation only and some of these were staged, with valves being 
inserted on two separate occasions one to two weeks apart. A radiologist blinded to 
clinical outcome assessed CT evidence of atelectasis, defined as changes in the 
position of interlobar fissures adjacent to the targeted area in CT scans performed one 
month post procedure. 
 
Spirometry, gas transfer and lung volumes assessed by body plethysmography were 
measured using a CompactLab System (Jaeger, Hoechberg, Germany). PaO2 and 
PaCO2 were measured in arterialized earlobe capillary samples. Quality of life was 
assessed using the St George’s respiratory questionnaire (SGRQ) and the Short form-
36 (SF-36). 
 
Patients performed endurance cycle ergometry, at 80% of the maximum workload 
achieved on a previous incremental test, before and after BLVR. Improvers were 
defined as those who had >60 seconds and 30% increase in endurance time. 
 
Pre-treatment CT scans of all subjects were analyzed using Pulmo-CMS software 
(Medis Specials, Leiden, The Netherlands).  Quantitative densitometry was performed 
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by calculating the Relative Area (RA) of pixel values below -950 Hounsfield Units in 
12 axial partitions of equal volume in each lung [20]. The top and bottom partitions 
were excluded to prevent influence by partial volume effects, and each lung was then 
characterized by its RA slope, defined as the slope in the plot of RAs against 
partitions. 
 
The ADO score (age, dyspnoea, obstruction) was calculated to allow us to quantify 
expected three year mortality in the patients at baseline [21]. 
 
Statistical analysis 
Baseline parameters in patients with and without atelectasis were compared using 
appropriate test for paired comparisons. Primary analysis was survival at 6 years 
follow up in individuals with or without atelectasis. A secondary analysis compared 
survival in exercise ‘improvers.’ Other treatment response characteristics of survivors 
were compared to those who had not survived. All ‘treatment response’ parameters 




Baseline characteristics of patients with (n=5) or without (n=14) atelectasis are given 
in Table 1. At 6 years, all five of the atelectasis group were still alive whereas 8 (57%) 
of the 14 non-atelectasis group had died (Chi2 p=0.026) (Figure 1). Death certificate 
data showed that 6 deaths were from respiratory failure, one was cardiovascular and 
one was due to lung cancer. In a stepwise regression model atelectasis was retained as 
an independent correlate of survival at 6 years (R 0.51 p=0.026) whereas FEV1 % 
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predicted, age and BMI were not. If the two non-respiratory deaths are excluded there 
is still a significant association between the occurrence of atelectasis and survival at 6 
years (Chi2 3.9 p=0.049) 
 
With the exception of BMI, which was significantly higher in the atelectasis group; 
28.4(2.9) vs 21.6(2.9) kgm-2 (p<0.001), there were no significant differences between 
the two groups at baseline in spirometry, lung volumes, gas transfer, blood gas 
parameters, quality of life, number of exacerbations in the preceding year or exercise 
capacity (assessed both by incremental shuttle walking test and cycle ergometry). In 
patients who did not have atelectasis there was no difference in BMI between those 
who were or were not alive at 6 years; 21.5(12.5) kgm-2 vs 21.7(6.6) kgm-2 (p=0.9). 
 
Pre treatment CT appearances did not differ significantly between the atelectasis and 
non-atelectasis groups in terms of degree of emphysema at either the upper or lower 
parts of the lungs or in heterogeneity (slope) in either the treated or non-treated lung 
prior to treatment. Using the ADO score, predicted 3 year mortality was 31.1(10.0)% 
in the non-atelectasis group and 32.2(15.1)% in the atelectasis group (p=0.8). 4 of the 
8 deaths occurred within 3 years of the procedure, representing a 16% three year 
mortality rate for the whole study group and a 29% mortality rate for the non-
atelectasis group. 
 
Acute effects of BLVR 
As reported previously, BLVR was associated with an increase in cycle endurance 
time from 227(129) secs to 315(195) seconds (p=0.03), a fall in functional residual 
capacity from 7.1(1.5) to 6.6(1.7)L (p=0.03),  and an increase diffusing capacity from 
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3.3(1.1) to 3.7(1.2) mmol.minute-1.kPa-1 (p=0.03). Nine patients were defined as 
improvers in the original study on the basis of their exercise capacity. At 6 years, 
2(22%) of the improvers and 6 (60%) of the non-improvers had died (p=0.06) (Figure 
2).  
 
Comparison of early responses between patients who had died or were still alive at six 
years are given in table 2. Of note, although survivors had numerically better 
responses for all parameters, only the occurrence of atelectasis was significantly 
different between groups.  
 
Late complications 
In the atelectasis group, as previously reported, one pneumothorax requiring 
intercostal drainage occurred at day two and one, which resolved without intervention, 
occurred at 4 weeks. There were no pneumothoraces in the non-atelectasis group. 
Subsequently one patient who had atelectasis developed a distal lung infection 
requiring drainage 6 years post procedure and one patient without atelectasis 
developed an ipsilateral empyema 2 years post procedure. 
 
Follow up imaging was not performed systematically, but CT or chest x-ray 
appearances were consistent with persisting atelectasis in all patients for at least one 
year (mean follow up at time of imaging 5.5 years) where this had been present at the 
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The main finding of this study is that the occurrence of atelectasis following BLVR 
for severe emphysema is associated with prolonged survival, with 100% alive at 6 
years compared to only 43% of individuals where atelectasis had not occurred. The 
only parameter that differed at baseline was BMI, which was significantly higher in 
the atelectasis group, but BMI was not itself independently associated with survival. 
 
Significance of findings 
The first possibility is that the survival advantage is explained by a difference in the 
baseline characteristics of the participants i.e. that some factor predisposing 
individuals to develop atelectasis also improved outcomes. A number of factors have 
been associated with survival in COPD including lung function parameters, exercise 
capacity, breathlessness and exacerbation frequency [22]. The participants in this 
study were thoroughly phenotyped (Table 1) and did not differ significantly at 
baseline in any parameter except in their BMI, which was higher in the atelectasis 
group. Exacerbation rate and quality of life were numerically but not significantly 
worse in the atelectasis group at baseline. A low BMI (<21) is an element of the 
BODE index which predicts survival in COPD although it wields only a modest effect 
and did not differ between survivors and non-survivors in the atelectasis group [23]. 
The lack of difference in BMI between survivors and non-survivors in the non-
atelectasis group suggests that it was not a significant factor determining survival and 
it is unlikely to be the explanation for the marked difference in outcome we observed. 
Moreover, in a study from our group based on a similar hospital-based COPD cohort, 
following 110 patients with a mean FEV1 of 36.6% predicted for up to five years, 
BMI did not differ between  those who had died (n=37) and survivors (n=73); 25(6.4) 
kgm-2 vs 25.1(6.4) kgm-2 [24]. 
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Another possibility is that the presence of atelectasis led to a systematic difference in 
the way that patients were treated subsequently that influenced survival. Patients were 
on standard optimal inhaled therapy already and it is likely that if a change occurred at 
all it would have led to a reduction in therapy in the atelectasis group so it is not clear 
how this would have conferred a survival advantage. 
 
There are a number of factors by which atelectasis might provide a survival advantage 
in patients with severe emphysema. Lung volume reduction surgery is associated with 
improved survival and exercise capacity in subgroups with low exercise capacity and 
heterogeneous disease [2], and is also associated with an improvement in diaphragm 
strength [25] and a reduction in the oxygen cost of breathing [26]. Successful BLVR, 
where atelectasis occurred, is likely to have mimicked the effects of LVRS by 
reducing operating lung volumes. Measures of gas trapping IC/TLC ratio[27] and 
sniff nasal pressure [24] have been shown to be associated with mortality in COPD, 
and both lung volumes and diaphragm function improved most in the atelectasis 
patients [14]. In this study cohort dynamic hyperinflation also improved most in 
patients with atelectasis. Dynamic hyperinflation has been shown to be associated 
with reductions in daily physical activity [28] which is itself associated with 
accelerated disease progression [29] and increased co-morbidity [30]. Interestingly a 
reduction in systemic inflammation has been observed following LVRS [31] – the 
authors of that study suggest that this is because of the removal of diseased lung but 
an alternative hypothesis is that a reduced work of breathing leads to a reduction in 
sympathetic activation [32] and reduced cardiac compromise from hyperinflation 
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[33]. This would be an interesting hypothesis to test in subsequent studies with BLVR 
approaches.  
 
None of the deaths in our cohort occurred within 6 months of the procedure, making it 
unlikely that they were related directly to complications of the procedure itself, which 
continues to have a better safety profile than LVRS [2, 9, 16].  
 
The current data suggest a survival benefit associated with improvement in functional 
capacity as there were fewer deaths in the ‘improvers’ group, defined as those with a 
>60 second improvement in endurance cycle time, though this is less clear cut than 
the effect of atelectasis. Interestingly although survivors tended to have had a better 
lung function and exercise response to BLVR at one month (Table 2) the only 
response parameter that was significantly different between the two groups was the 
occurrence of atelectasis. 
 
Implications for targeting strategy 
In a multicentre series of 98 patients treated with Emphasys valves, 5 pneumothoraces 
occurred, 3 requiring surgical intervention [9]. All pneumothoraces occurred where 
lobar occlusion had been performed. In that study, a lobar targeting strategy produced 
significantly better improvements in FEV1 and exercise capacity than a nonlobar 
approach. Likewise, a unilateral approach led to greater benefits in FEV1 and exercise 
capacity than a bilateral approach. No data on radiological atelectasis were presented 
however. There were no obstructive pneumonias and in fact 5 pneumonias occurred in 
non-targeted lobes during the 90 day follow up period. 
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The VENT study (Endobronchial Valve for Emphysema Palliation Trial) was a 
randomized controlled trial studying the addition of BLVR to best supportive care 
including pulmonary rehabilitation. A unilateral lobar targeting strategy was adopted. 
The study results have not yet been published fully, but the BLVR intervention was 
associated with an improvement in FEV1 and exercise capacity [4]. Functional 
improvement and reduction in lobar volume were greatest in those with intact 
interlobar fissures, the absence of defects being a marker for reduced collateral 
ventilation [34].  
 
In contrast to the unilateral lobar occlusion strategy, a bilateral approach with 
incomplete lobar occlusion has also been advocated in trials with the umbrella-shaped 
IBV valve (Spiration Inc, Redmond, Wash, USA). A review of experience in 98 
subjects undergoing bilateral valve placement found that although treatment was 
associated with changes in lobar volume and improvements in quality of life (which 
must be interpreted with great caution in the absence of a control group), there were 
no changes in lung function parameters. Interestingly this group also found that where 
atelectasis, which occurred in 9(9%) subjects, was present it was associated with 
significant improvements in lung volumes as well as larger improvements in 
SGRQ[16]. Pneumothorax occurred in 5 (56%) atelectasis patients and 6 (7%) of the 
non-atelectasis patients. Longer term follow up data from that cohort is not available. 
 
Limitations of the study 
 
The study is relatively small and confirmation from larger cohorts and trials is 
necessary. An incremental shuttle walk test was used rather than the 6 minute walk 
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test, so it was not possible to calculate the BODE score for these patients. However 
the ADO index suggests an expected 3 year mortality of more than 30 percent in the 
whole cohort, similar to the 29% 3 year mortality observed in the non-atelectasis 
group. This suggests that the finding of prolonged survival in the atelectasis group 
differs significantly from what would have been expected. 
 
Conclusion 
These data suggest that where BLVR is successful in producing atelectasis this 
imparts a significant survival advantage.  The data also illustrate that longer term 
follow up is needed to evaluate fully the risks and benefits of bronchoscopic lung 
volume procedures. 
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Figure 1  
Atelectasis following BLVR was associated with improved survival (p=0.026). 
 
Figure 2  
There were fewer deaths among patients with a significant improvement in exercise 
capacity after BLVR (p=0.06). 
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Age 59.6(9.0) 56.0(7.6) 0.4 
Percent female 14 20 0.7 
BMI (kg.m-2) 21.6(2.9) 28.2(2.9) 0.004 
SNiP (cmH2O) 64.4(22.9) 70.6(26.3) 0.6 
FFMI (kg.m-2) 15.8(1.5) 17.5(1.4) 0.05 
SGRQ Symptoms 63.3(18.2) 64.9(24.3) 0.9 
SGRQ Activity 76.9(18.1) 83.2(11.0) 0.5 
SGRQ Impacts 42.8(13.9) 51.9(11.0) 0.2 
SGRQ Total 56.5(14.2) 63.5(5.3) 0.3 
SF-36 PCS 41.2(19.9) 41.9(16.9) 0.9 
SF-36 MCS 50.5(23.4) 50.7(19.3) 0.9 
FEV1 %pred 28.6(11.8) 27.7(13.3) 0.9 
FVC %pred 80.1(18.2) 81.0(34.3) 0.9 
TLC %pred 141.1(16.0) 134.3(14.7) 0.4 
RV %pred 264.4(66.6) 249.4(80.0) 0.7 
RV/TLC (%) 64.0(10.8) 60.9(16.1) 0.6 
FRC %pred 213.3(37.9) 200.1(44.1) 0.5 
TLco %pred 35.6(11.2) 36.9(11.1) 0.8 
PaCO2 (kPa) 4.8(0.5) 4.8(0.8) 0.9 
PaO2 (kPa) 10.0(1.4) 9.2(1.7) 0.3 
Exacerbation rate /yr 1.9(1.5) 2.8(2.7) 0.4 
ADD prednisone mg/day 3.1(6.3) 4.1(5.6) 0.8 
Pack years smoked 45.4(16.7) 58.6(21.9) 0.2 
VO2 l/min 0.85(0.23) 0.85(0.26) 0.99 
VCO2 l/min 0.79(0.27) 0.79(0.23) 0.98 
VE l/min 29.5(9.9) 29.5(4.1) 0.99 
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Values are Mean (SD). BMI body mass index, SNiP sniff nasal inspiratory pressure, 
FFMI fat free mass index, SGRQ St George’s Respiratory Questionnaire, SF-36 short 
form 36, PCS physical component score, MCS mental component score, FEV1 forced 
expiratory volume in one second, TLCO diffusing capacity, TLC total lung capacity, 
RV residual volume, FRC functional residual capacity. ADD average daily dose in the 
preceding year, VO2 oxygen consumption, VCO2 carbon dioxide production, VE 
minute ventilation.  
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Table 2 Comparison of early responses to BLVR in survivors and non-survivors 
 Non-survivor at 
6 years 
=8 




∆ SWT (m) +17.5 (65) 20.9(95) 0.9 
∆ TLco (mmol.minute-1.kPa-1) +0.11(0.4) +0.46(0.6) 0.2 
∆ RV (L) -0.01(0.4) -0.62(1.2) 0.37 
∆ TLC (L) -0.17(0.28) -0.31(0.55) 0.53 
∆ FRC (L) -0.26(0.41) -0.49(0.86) 0.53 
∆ Endurance time (secs) +26.5(148) +133 (172) 0.17 
∆ FEV1 (L) -0.01(0.17) +0.18(0.2) 0.06 
∆ Isotime EELV (L) -0.16(0.56) -0.61(1.0) 0.31 
∆ SGRQ  -0.6(10.6) -0.1(8.4) 0.9 
Atelectasis (n) 0 5(45%) 0.026* 
 
Values are Mean (SD). SWT shuttle walk test,  TLCO diffusing capacity, RV residual 
volume, TLC total lung capacity, Endurance time refers to performance on a cycle 
ergometer at 80% of peak workload, FEV1 forced expiratory volume in one second, 
EELV end expiratory lung volume, SGRQ St George’s respiratory questionnaire total 
score. P values are for unpaired t tests except *Chi2. 
